EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension

Samer Alabed iD, Pankaj Garg, Faisal Alandejani iD, Krit Dwivedi, Ahmed Maiter, Kavita Karunasaagarar, Smitha Rajaram, Catherine Hill, Steven Thomas, Rebecca Gossling, Michael J Sharkey iD, Mahan Salehi und 15 weitere

European Respiratory Journal · 2023

DOI: 10.1183/13993003.02225-2022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Samer Alabed und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK s.alabed@nhs.net. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Ventricular Dysfunction, Right. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, British Heart Foundation, Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiac magnetic resonance (CMR) is the gold standard technique to assess biventricular volumes and function, and is increasingly being considered as an end-point in clinical studies. Currently, with the exception of right ventricular (RV) stroke volume and RV end-diastolic volume, there is only limited data on minimally important differences (MIDs) reported for CMR metrics. Our study aimed to identify MIDs for CMR metrics based on US Food and Drug Administration recommendations for a clinical outcome measure that should reflect how a patient “feels, functions or survives”.

Methods

Consecutive treatment-naïve patients with pulmonary arterial hypertension (PAH) between 2010 and 2022 who had two CMR scans (at baseline prior to treatment and 12 months following treatment) were identified from the ASPIRE registry. All patients were followed up for 1 additional year after the second scan. For both scans, cardiac measurements were obtained from a validated fully automated segmentation tool. The MID in CMR metrics was determined using two distribution-based (0.5 sd and minimal detectable change) and two anchor-based (change difference and generalised linear model regression) methods benchmarked to how a patient “feels” (emPHasis-10 quality of life questionnaire), “functions” (incremental shuttle walk test) or “survives” for 1-year mortality to changes in CMR measurements.

Results

254 patients with PAH were included (mean± sd age 53±16 years, 79% female and 66% categorised as intermediate risk based on the 2022 European Society of Cardiology/European Respiratory Society risk score). We identified a 5% absolute increase in RV ejection fraction and a 17 mL decrease in RV end-diastolic or end-systolic volumes as the MIDs for improvement. Conversely, a 5% decrease in RV ejection fraction and a 10 mL increase in RV volumes were associated with worsening.

Conclusions

This study establishes clinically relevant CMR MIDs for how a patient “feels, functions or survives” in response to PAH treatment. These findings provide further support for the use of CMR as a clinically relevant clinical outcome measure and will aid trial size calculations for studies using CMR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionVentricular Dysfunction, RightHumansFemaleAdultMiddle AgedAgedMaleQuality of LifeMagnetic Resonance ImagingStroke VolumeFamilial Primary Pulmonary HypertensionVentricular Function, RightPredictive Value of Tests

Autor:innen und Institutionen

  • Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK s.alabed@nhs.net.
  • Department of Clinical Radiology, Sheffield Teaching Hospitals, Sheffield, UK.
  • INSIGNEO, Institute for in silico Medicine, University of Sheffield, Sheffield, UK.
  • Norwich Medical School, University of East Anglia, Norwich, UK.
  • Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.

ORCID-Profile: Samer Alabed, Faisal Alandejani, Michael J Sharkey, Abdul Hameed, A A Roger Thompson, Robin Condliffe, David G Kiely

Förderung

  • Wellcome Trust
  • British Heart Foundation
  • Department of Health
  • NIHR Sheffield Biomedical Research Centre
  • National Institute for Health and Care Research

Zitieren

APA

Alabed, S., Garg, P., Alandejani, F., Dwivedi, K., Maiter, A., Karunasaagarar, K., Rajaram, S., Hill, C., Thomas, S., Gossling, R., Sharkey, M. J., Salehi, M., Wild, J. M., Watson, L., Hameed, A., Charalampopoulos, A., Lu, H., Rothman, A. M. K., Thompson, A. A. R., …, & Kiely, D. G. (2023). Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension. European Respiratory Journal. https://doi.org/10.1183/13993003.02225-2022

Vancouver

Alabed S, Garg P, Alandejani F, Dwivedi K, Maiter A, Karunasaagarar K, et al. Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension. European Respiratory Journal. 2023. doi:10.1183/13993003.02225-2022

BibTeX
@article{Alabed2023,
  author = {Alabed, Samer and Garg, Pankaj and Alandejani, Faisal and Dwivedi, Krit and Maiter, Ahmed and Karunasaagarar, Kavita and Rajaram, Smitha and Hill, Catherine and Thomas, Steven and Gossling, Rebecca and Sharkey, Michael J and Salehi, Mahan and Wild, Jim M and Watson, Lisa and Hameed, Abdul and Charalampopoulos, Athanasios and Lu, Haiping and Rothman, Alex M K and Thompson, A A Roger and Elliot, Charlie A and Hamilton, Neil and Johns, Christopher S and Armstrong, Iain and Condliffe, Robin and van der Geest, Rob J and Swift, Andrew J and Kiely, David G},
  title = {Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension},
  journal = {European Respiratory Journal},
  year = {2023},
  doi = {10.1183/13993003.02225-2022}
}
Kostenlos starten →